Orthocell bets on prostate surgery as five patient pilot paves way for US push

Latest News

Perth-based regenerative medicine company Orthocell says its nerve repair device could open a new market in prostate cancer surgery.

The company told investors that Remplir, its collagen device already approved for peripheral nerve reconstruction, had shown "excellent early functional recovery" when placed over the prostate nerves of men having robotic surgery for advanced prostate cancer.

The company said it will use the pilot to shape a larger prospective trial and to prepare a launch in the United States, where Remplir is already cleared, and no further FDA approval is needed.

The five men were aged 57 to 69, and most had conditions such as diabetes, high blood pressure and obesity that can make recovery harder. Some had urinary symptoms or erectile dysfunction before surgery. In every case, the cancer had grown beyond the outer edge of the prostate. Two tumours were high grade, and three were intermediate grade. Surgeons had to remove the nerves on the affected side and could preserve only part of the nerve tissue on the other, which made recovery of continence and erectile function even harder.

Urological surgeon Dr Peter Chong said those circumstances made the early results notable. "I am encouraged by these early results, particularly given that these patients underwent limited nerve-sparing surgery. In this setting, recovery of urinary and sexual function can be challenging, so seeing these functional outcomes at this early stage is promising. The technique does not add significant operating time, and I look forward to building on these results as we treat more patients and continue to strengthen the clinical evidence."

The surgical robot placed Remplir over the nerve regions in all five patients with no technical difficulties or significant extra operating time. No device-related complications were reported during surgery or over about 12 months of follow-up.

Managing director Paul Anderson said, "This pilot did what a first series should. It showed Remplir can be placed reliably in a difficult and variable nerve-sparing setting, and it provided early safety, usability and functional data. The next step is a larger, adequately powered, prospective trial to support use of Remplir in improving recovery of erectile function and continence after nerve-sparing robotic prostatectomy."

Australian surgeons are already using the device. Remplir has been used in more than 300 prostatectomies, several surgeons use it routinely, and some have done more than 20 procedures with it. More than 12,000 robotic-assisted radical prostatectomies are performed in Australia each year. In the United States, the figure is about 115,000 prostatectomies a year, most of them robotic. Published research estimates that up to 75 per cent of patients undergoing the operation may be suitable for nerve-sparing techniques, and that more than one device can be used in a single procedure.

Orthocell estimates prostate surgery could lift its estimated US total addressable market for Remplir from US$1.6 billion to about US$2.0 billion. The device is approved in Australia, New Zealand, the United States, Canada, Singapore, Hong Kong and Thailand, and the company does not need further regulatory clearance for prostatectomy use in any of those markets.